Reston, VA, September 26, 2018- Brillient Corporation has been awarded a $9M contract with The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to provide technical services and administrative support. This is a delivery order against Brillient’s GSA, PSS Schedule, with a three year period of performance. The contract focuses on enhancing the NIDDK mission to conduct and support medical research, research training and to disseminate science-based information on diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, obesity, kidney, urologic and hematologic diseases, to improve people’s health and quality of life. “The NIH has a very important mission in the fight against disease and ensuring a healthier future. We are pleased to be supporting NIDDK on their valuable mission”, said Sukumar Iyer, Brillient’s CEO. “Brillient’s proven experience and demonstrated success in timely delivery of mission outcomes makes Brillient an ideal partner in support of the NIDDK mission”.